3B BlackBio Dx Ltd — Important, 23-08-2025: Company Update

Company leadership discussed first quarter financial results, with sales growing 18% to INR 19.96 Cr and EBITDA increasing 11% to INR 16.19 Cr. The company holds a 12-15% share of the Indian molecular diagnostic market, projected to grow 15-20% this fiscal year. A strategic acquisition of Coris Holding SRL, a European rapid diagnostic solutions manufacturer, for GBP 2.765 million (including earn-outs) was announced. Coris, with EUR 5.22 million revenue and unique AMR products, is expected to become EBITDA positive by 2026-27, targeting EUR 7-8 million top line within 3-4 years through expanded market reach, new product launches, and cross-selling.